文献速递产科母胎医学

双胎妊娠中游离DNA筛查21三体的多中心大样本队列研究

Cell-free DNA screening for trisomy 21 in twin pregnancy: a large multicenter cohort study.
PubMed 文献 · Am J Obstet Gynecol · 2023-04-06

这项回顾性多中心队列研究纳入17个中心2011年12月至2020年2月期间进行游离DNA筛查的双胎妊娠,最终分析1447例。21三体检测率为97.6%(95%CI 83.8-99.7),双绒毛膜双胎中为97.4%(95%CI 82.6-99.7),不可报告率为3.9%。作者认为游离DNA从早孕期起对双胎21三体筛查有效,但18三体和13三体例数太少,尚不能就筛查效能做出确切结论。

要点

  • 双胎妊娠游离DNA筛查21三体检测率97.6%(95%CI 83.8-99.7),1例假阴性、无假阳性。
  • 双绒毛膜双胎21三体检测率97.4%(95%CI 82.6-99.7),38/39例检出。
  • 不可报告率低,为3.9%;18三体和13三体例数太少,尚不能得出确切结论。

核心结论

  • 游离DNA从早孕期起对双胎妊娠21三体筛查有效,双绒毛膜和单绒毛膜双胎中21三体检测率均高,不可报告率低。
  • 与现有文献相比,本研究纳入的18三体和13三体例数较多,但这些疾病筛查看起来有前景,例数太少尚不能就筛查效能做出确切结论。
  • 游离DNA检测性能可能因实验室而异,并随筛查方法学不同而变化。

研究设计与样本

  • 回顾性队列研究,纳入17个中心2011年12月至2020年2月期间由同一实验室采用大规模平行测序技术进行游离DNA筛查的双胎妊娠。
  • 共1764例样本送检,排除78例双胎消失和239例随访信息不足者,最终纳入1447例分析。
  • 中位母亲年龄35岁,游离DNA检测中位孕周12.3周,81%为双绒毛膜双胎,中位胎儿分数12.4%。
  • 要求至少35例确诊21三体以在患病率至少1.9%时以80%把握度捕获至少90%的敏感度。

主要发现

  • 21三体在42例妊娠中检出41例,检测率97.6%(95%CI 83.8-99.7),1例假阴性、无假阳性。
  • 双绒毛膜双胎中21三体在39例妊娠中检出38例,检测率97.4%(95%CI 82.6-99.7)。
  • 18三体在10例受累妊娠中全部检出,有1例假阳性。
  • 13三体在5例中检出4例,检测率80%(95%CI 11.1-99.2),1例假阴性、无假阳性。
  • 不可报告率为3.9%。

临床怎么用

  • 作者认为游离DNA检测对双胎妊娠从早孕期起筛查21三体有效。
  • 作者指出18三体和13三体筛查看起来有前景,但例数太少尚不能就筛查效能做出确切结论。

局限性

  • 18三体和13三体例数太少,尚不能就筛查效能做出确切结论。
  • 游离DNA检测性能可能因实验室而异,并随筛查方法学不同而变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Analysis of cell-free DNA from maternal blood provides effective screening for trisomy 21 in singleton pregnancies. Data on cell-free DNA screening in twin gestations are promising although limited. In previous twin studies, cell-free DNA screening was primarily performed in the second trimester and many studies did not report chorionicity. OBJECTIVE: This study aimed to evaluate the screening performance of cell-free DNA for trisomy 21 in twin pregnancies in a large, diverse cohort. A secondary aim was to evaluate screening performance for trisomy 18 and trisomy 13. STUDY DESIGN: This was a retrospective cohort study of twin pregnancies from 17 centers for which cell-free DNA screening was performed from December 2011 to February 2020 by one laboratory using massively parallel sequencing technology. Medical record review was conducted for all newborns and data on the birth outcome, the presence of any congenital abnormalities, phenotypic appearance at birth, and any chromosomal testing that was undertaken in the antenatal or postnatal period were extracted. Cases with a possible fetal chromosomal abnormality with no genetic test results were reviewed by a committee of maternal-fetal medicine geneticists. Cases with a vanishing twin and inadequate follow-up information were excluded. A minimum of 35 confirmed cases of trisomy 21 was required to capture a sensitivity of at least 90% with a prevalence of at least 1.9% with 80% power. Test characteristics were calculated for each outcome. RESULTS: A total of 1764 samples were sent for twin cell-free DNA screening. Of those, 78 cases with a vanishing twin and 239 cases with inadequate follow-up were excluded, leaving a total of 1447 cases for inclusion in the analysis. The median maternal age was 35 years and the median gestational age at cell-free DNA testing was 12.3 weeks. In total, 81% of the twins were dichorionic. The median fetal fraction was 12.4%. Trisomy 21 was detected in 41 of 42 pregnancies, yielding a detection rate of 97.6% (95% confidence interval, 83.8-99.7). There was 1 false negative and no false positive cases. Trisomy 21 was detected in 38 out of 39 dichorionic twin pregnancies, yielding a detection rate of 97.4% (95% confidence interval, 82.6-99.7). Trisomy 18 was detected in 10 of the 10 affected pregnancies. There was 1 false positive case. Trisomy 13 was detected in 4 of the 5 cases, yielding a detection rate of 80% (95% confidence interval, 11.1-99.2). There was one false negative and no false positive cases. The nonreportable rate was low at 3.9 %. CONCLUSION: Cell-free DNA testing is effective in screening for trisomy 21 in twin gestations from the first trimester of pregnancy. Detection of trisomy 21 was high in dichorionic and monochorionic twins, and the nonreportable result rates were low. This study included high numbers of cases of trisomy 18 and 13 when compared with the current literature. Although screening for these conditions in twins seems to be promising, the numbers were too small to make definitive conclusions regarding the screening efficacy for these conditions. It is possible that cell-free DNA testing performance may differ among laboratories and vary with screening methodologies.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Dugoff L, Koelper NC, Chasen ST, et al. Cell-free DNA screening for trisomy 21 in twin pregnancy: a large multicenter cohort study. Am J Obstet Gynecol. 2023. PMID: 37030426. doi:10.1016/j.ajog.2023.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。